Role of insulin-like growth factor binding proteins in limitation of IGF-Idegradation into the N-methyl-D-aspartate receptor antagonist GPE: evidence from gonadotrophin-releasing hormone secretion in vitro at two developmental stages

Citation
Jp. Bourguignon et A. Gerard, Role of insulin-like growth factor binding proteins in limitation of IGF-Idegradation into the N-methyl-D-aspartate receptor antagonist GPE: evidence from gonadotrophin-releasing hormone secretion in vitro at two developmental stages, BRAIN RES, 847(2), 1999, pp. 247-252
Citations number
31
Categorie Soggetti
Neurosciences & Behavoir
Journal title
BRAIN RESEARCH
ISSN journal
00068993 → ACNP
Volume
847
Issue
2
Year of publication
1999
Pages
247 - 252
Database
ISI
SICI code
0006-8993(19991120)847:2<247:ROIGFB>2.0.ZU;2-K
Abstract
We showed previously that insulin-like growth factor-I (ICF-I) could inhibi t the secretion of gonadotrophin-releasing hormone (GnRH) evoked in vitro b y N-methyl-D-aspartate (NMDA) or veratridine depolarization. Such an IGF-I effect appeared to be mediated by its physiological breakdown product, the N-terminal tripeptide GPE. That effect was developmentally regulated since IGF-I could inhibit GnRH secretion from hypothalamic explants of 50-day-old adult rats but not from immature 15-day-old explants. We hypothesized that the IGF-binding proteins (BPs) could limit the peptide availability to end opeptidases and account for the absent IGF-I effects at 15 days. In this pa per, we show that the inhibition of GnRH secretion by 10(-10) M of IGF-I at 50 days is prevented in a dose-dependent manner by 0.3 to 3 nM of IGF-BP2 as well as IGF-BP3. The inhibition caused by 10(-10) M of GPE is not affect ed under similar conditions. Using explants obtained at 15 days, a signific ant inhibition of GnRH secretion can be obtained by 10(-10) M of IGF-I in t he presence of an anti IGF-BP2 antiserum used at 1:3000 and 1:1000 concentr ations. These data indicate that in the immature rat brain, the IGF-BPs cou ld act as modulators of IGF-I degradation into its subproduct GPE, a possib le endogenous antagonist at NMDA receptors. (C) 1999 Elsevier Science B.V. All rights reserved.